1. Home
  2. SNDX vs GRPN Comparison

SNDX vs GRPN Comparison

Compare SNDX & GRPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNDX
  • GRPN
  • Stock Information
  • Founded
  • SNDX 2005
  • GRPN 2008
  • Country
  • SNDX United States
  • GRPN United States
  • Employees
  • SNDX N/A
  • GRPN N/A
  • Industry
  • SNDX Biotechnology: Pharmaceutical Preparations
  • GRPN Advertising
  • Sector
  • SNDX Health Care
  • GRPN Consumer Discretionary
  • Exchange
  • SNDX Nasdaq
  • GRPN Nasdaq
  • Market Cap
  • SNDX 1.1B
  • GRPN 1.2B
  • IPO Year
  • SNDX 2016
  • GRPN 2011
  • Fundamental
  • Price
  • SNDX $14.75
  • GRPN $21.91
  • Analyst Decision
  • SNDX Strong Buy
  • GRPN Buy
  • Analyst Count
  • SNDX 10
  • GRPN 4
  • Target Price
  • SNDX $38.40
  • GRPN $31.25
  • AVG Volume (30 Days)
  • SNDX 2.0M
  • GRPN 1.3M
  • Earning Date
  • SNDX 11-04-2025
  • GRPN 11-11-2025
  • Dividend Yield
  • SNDX N/A
  • GRPN N/A
  • EPS Growth
  • SNDX N/A
  • GRPN N/A
  • EPS
  • SNDX N/A
  • GRPN N/A
  • Revenue
  • SNDX $77,933,000.00
  • GRPN $487,747,000.00
  • Revenue This Year
  • SNDX $585.73
  • GRPN $4.78
  • Revenue Next Year
  • SNDX $94.17
  • GRPN $10.96
  • P/E Ratio
  • SNDX N/A
  • GRPN N/A
  • Revenue Growth
  • SNDX 2126.66
  • GRPN N/A
  • 52 Week Low
  • SNDX $8.58
  • GRPN $7.75
  • 52 Week High
  • SNDX $22.50
  • GRPN $43.08
  • Technical
  • Relative Strength Index (RSI)
  • SNDX 47.48
  • GRPN 29.34
  • Support Level
  • SNDX $15.71
  • GRPN $22.12
  • Resistance Level
  • SNDX $16.50
  • GRPN $24.18
  • Average True Range (ATR)
  • SNDX 0.81
  • GRPN 1.04
  • MACD
  • SNDX -0.36
  • GRPN -0.03
  • Stochastic Oscillator
  • SNDX 2.73
  • GRPN 8.54

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

About GRPN Groupon Inc.

Groupon Inc acts as the middleman between consumers and merchants, offering products and services at discounts via its online store. It offers consumers daily deals from local merchants. The company's operations are organized into two segments: North America and International. The company generates the majority of its revenue from North America. The company generates revenue from transactions during which the company generates commissions by selling goods or services on behalf of third-party merchants. Revenue also includes commissions the company earn when customers make purchases with retailers using digital coupons accessed through its digital properties.

Share on Social Networks: